Pembrolizumab regimen extends OS in metastatic gastric, gastroesophageal junction cancers

The addition of pembrolizumab to chemotherapy improved OS among certain patients with gastric or gastroesophageal junction cancers, according to the agent’s manufacturer.Pembrolizumab (Keytruda, Merck) is an anti-PD-1 therapy.The randomized phase 3 KEYNOTE-859 trial evaluated the efficacy of chemotherapy plus pembrolizumab or placebo as first-line treatment for patients with HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal adenocarcinoma.Researchers randomly assigned 1,579 patients to fluoropyrimidine- and platinum-containing chemotherapy plus eitherRead More

Generated by Feedzy